Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD Heidelberg, Germany – 17 February 2026 – FundaMental…
Read More
FundaMental Pharma GmbH
Nikola-Tesla-Straße 1
D-69124 Heidelberg, Germany
